Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teva Pharmaceutical Industries Limited (TEVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the Securities and Exchange Commission. As an issuer with American Depositary Shares listed on the New York Stock Exchange under the symbol TEVA, Teva reports material events, financing arrangements and financial results through these filings.
Recent Form 8‑K filings include items on results of operations and financial condition, where Teva furnishes press releases announcing quarterly financial results for periods such as the quarters ended June 30 and September 30. These filings typically incorporate earnings press releases by reference and clarify that the information is being furnished rather than filed for purposes of the Exchange Act. Another 8‑K describes Teva’s presentation at a major healthcare conference and includes expectations regarding performance for the 2025 fiscal year.
Teva also uses Form 8‑K to disclose material definitive agreements and related direct financial obligations. For example, an 8‑K details the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, which extended the maturity date of the revolving facility and amended financial covenants such as the maximum leverage ratio and conditions tied to investment grade status. These filings provide insight into Teva’s capital structure, liquidity management and covenant framework.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the main points of each document in plain language. This includes highlighting key terms in credit agreements, summarizing earnings-related disclosures, and pointing out items that may affect leverage, liquidity or future reporting. Users interested in TEVA can use the filings page to track quarterly and annual reporting, current reports on material events, and disclosures related to financing arrangements, while AI tools help interpret lengthy or technical sections of the filings.
Teva Pharmaceutical Industries director equity update: A Teva director reported the vesting and settlement of 4,804 restricted share units into the same number of ordinary shares on 12/02/2025, shown as an "M" (conversion) transaction. Following this transaction, the director beneficially owns 4,804 ordinary shares, held directly.
These restricted share units were originally granted on December 2, 2024 and vested on December 2, 2025. Each restricted share unit entitled the holder to receive one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share. Teva’s ordinary shares may also be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
Teva Pharmaceutical Industries Ltd. director reports share sale. A reporting person serving as a director of Teva Pharmaceutical Industries Ltd. (TEVA) sold 50,000 Ordinary Shares on 11/26/2025 in an open-market transaction coded "S" for sale. The shares were sold at a weighted average price of
After this transaction, the reporting person is shown as beneficially owning 445,000 Ordinary Shares indirectly through Swiftcurrent Master Fund Ltd. and 105,315 Ordinary Shares directly. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share, and that certain indirect holdings are disclaimed except for any indirect pecuniary interest.
Teva Pharmaceutical Industries (TEVA) executive Christine Fox reported equity compensation activity and a related share sale. On 11/20/2025, 63,492 restricted share units vested and were settled into the same number of ordinary shares. On the same date, she sold 28,229 ordinary shares at $24.7803 per share, with the filing stating this represented shares required to be sold to cover tax withholding obligations tied to the vesting.
The sale was carried out under a Rule 10b5-1 trading plan adopted on August 11, 2025. After these transactions, Fox directly beneficially owned 63,647 ordinary shares and held 126,984 restricted share units that may settle into additional ordinary shares or their cash value under the company’s compensation arrangements.
Teva Pharmaceutical Industries Ltd. insider plans share sale under Rule 144. A holder has filed to sell 28,229 ordinary shares through Citigroup Global Markets Inc. on the NYSE, with an aggregate market value of $699,523.09. The filing notes that 1,147,282,512 ordinary shares were outstanding at the time of the notice.
The seller acquired 63,492 ordinary shares on 11/20/2025 via restricted stock vesting from Teva as compensation, and payment was characterized as compensation rather than cash. Over the past three months, the same person sold 30,000 ordinary shares on 11/14/2025 for gross proceeds of $753,321.00. By signing, the seller represents they are not aware of undisclosed material adverse information about Teva’s operations.
Teva Pharmaceutical Industries Ltd. (TEVA) reported an insider stock sale by its EVP, Head of U.S. Commercial. On 11/14/2025, the executive sold 30,000 Ordinary Shares in an open market transaction at a price of $25.1107 per share, reported under transaction code "S" for a sale. After this transaction, the executive beneficially owns 28,384 Ordinary Shares, held directly. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
Teva Pharmaceutical Industries (TEVA) received a Form 144 notice for a planned sale of up to 30,000 ordinary shares. The filing lists an aggregate market value of $753,321, with an approximate sale date of 11/14/2025. The proposed broker is Citigroup Global Markets Inc., and the shares are listed on the NYSE. The seller reports acquiring the shares on 11/20/2024 via a shares from rollover transaction, with the consideration described as compensation.
TEVA Pharmaceutical Industries (TEVA) reported an insider transaction by director Roberto Mignone. On 11/06/2025, he sold 200,000 Ordinary Shares (transaction code S) at a weighted average price of $24.1094.
Following the sale, he beneficially owned 495,000 Ordinary Shares indirectly through Swiftcurrent Master Fund Ltd. and 105,315 Ordinary Shares directly. The filing notes that TEVA’s Ordinary Shares may be represented by ADSs, each currently representing one Ordinary Share.
Teva Pharmaceutical Industries (TEVA) disclosed an insider transaction on Form 4. Chief Accounting Officer Amir Weiss sold 12,300 ordinary shares on 11/06/2025 at a weighted average price of $24.4361, with trades ranging from $24.435 to $24.455. Following the sale, he beneficially owns 17,950 shares, held directly. The filing notes that Teva’s ordinary shares may be represented by ADSs, each currently equal to one ordinary share.
TEVA: An amended Form 144 was filed for the proposed sale of 200,000 American Depositary Shares. The filing lists Piper Sandler & Co. as broker, an aggregate market value of $4,920,000, and an approximate sale date of 11/06/2025 on the NYSE.
The shares to be sold were acquired on 05/09/2018. As context, the filing reports 1,147,282,512 shares outstanding. This notice outlines a potential secondary sale by a holder and does not describe any new issuance.
Teva Pharmaceutical Industries reported Q3 2025 results showing higher profitability. Net revenues were $4,480 million, up from $4,332 million a year ago. Operating income reached $882 million versus a loss last year, and net income attributable to Teva was $433 million (basic EPS $0.38; diluted $0.37). For the first nine months, net revenues were $12,547 million with net income of $930 million.
The balance sheet reflects $2,203 million in cash and cash equivalents, total assets of $39,856 million, and Teva shareholders’ equity of $7,250 million. Senior notes and loans were $16,766 million. Teva executed several 2025 note repayments and, in May 2025, issued new senior notes of $700 million (5.75% due 2030), €1,000 million (4.125% due 2031) and $500 million (6.00% due 2032). A June 2025 tender extinguished multiple tranches, resulting in a $10 million loss recorded in financial expenses. Shares outstanding were 1,147,282,512 as of September 30, 2025.
FAQ
What is the current stock price of Teva Pharm (TEVA)?
What is the market cap of Teva Pharm (TEVA)?
